You are here: Home: OPU 1 | 2006 : Case 1: Select publications

SELECT PUBLICATIONS

Bucaneve G et al; Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Infection Program. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005;353(10):977-87. Abstract

Citron ML et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21(8):1431-9. Abstract

Cosler LE et al. Economic analysis of pegfilgrastim in patients receiving cancer chemotherapy. Proc ASCO 2005;Abstract 6041.

Eiermann W et al. Phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (ACT) in HER-2/neu negative early breast cancer patients with positive axillary lymph nodes: Interim analysis of the BCIRG 005 study. San Antonio Breast Cancer Symposium 2005;Abstract 1069.

Hudis C et al. Five year follow-up of INT C9741: Dose-dense (DD) chemotherapy (CRx) is safe and effective. San Antonio Breast Cancer Symposium 2005;Abstract 41.

Kuderer NM et al. Meta-analysis of prophylactic granulocyte colony-stimulating factor (G-CSF) in cancer patients receiving chemotherapy. Proc ASCO 2005;Abstract 8117.

Lyman GH. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: A review of the evidence. J Natl Compr Cancer Netw 2005a;3(4):557-71. Abstract

Lyman GH et al. A risk model for first cycle febrile neutropenia in cancer patients receiving systemic chemotherapy. Proc ASCO 2005b;Abstract 8122.

Martin M et al; Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005a;352(22):2302-13. Abstract

Martin M et al. Multicenter, randomized phase III study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FE90C versus 4 cycles of FE90C followed by 8 weekly paclitaxel administrations: Interim efficacy analysis of GEICAM 9906 Trial. San Antonio Breast Cancer Symposium 2005b;Abstract 39.

NCCN Clinical Practice Guidelines in Oncology — Myeloid Growth Factors in Cancer Treatment Version 2.2005.

Olivotto IA et al. Population-based validation of the prognostic model Adjuvant! for early breast cancer. J Clin Oncol 2005;23(12):2716-25. Abstract

Roche H et al. Five years analysis of the PACS 01 trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel (D) for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium 2004;Abstract 27.

Vogel CL et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005;23(6):1178-84. Abstract

Wolff D et al; Awareness of Neutropenia in Chemotherapy Study Group. Predictors of chemotherapy- induced neutropenia and its complications: Results from a prospective nationwide registry. J Support Oncol 2005;3(6 Suppl 4):24-5. No abstract available

 

Table of Contents

Top of Page